Abstract
While smoking cessation leads to significant improvements in both mortality and morbidity, post-cessation weight gain partially attenuates this benefit. Even though post-cessation weight gain is small (4.7 kg on average), it is a stated reason to delay cessation attempts and is associated with smoking relapse. Fit & Quit is a randomized, controlled efficacy trial that aims to examine the ability of a weight stability intervention and a weight loss intervention to reduce post-cessation weight gain. For this purpose, Fit & Quit will randomize participants to three conditions: (a) Small Changes, a weight gain prevention intervention; (b) Look AHEAD Intensive Lifestyle Intervention; and (c) a lower-intensity bibliotherapy intervention. All conditions will receive a highly efficacious behavioral (i.e., rate reduction skills, motivational interviewing) and pharmacological (i.e., varenicline) smoking cessation program. A total of 400 participants will be recruited and randomized to the three interventions. Participants will be recruited in waves, with 10 waves of approximately 40 participants per wave. The primary outcomes of this study include post-cessation weight gain and cessation status at 12-month follow-up. Fit & Quit will integrate and adapt the strongest evidence-based interventions available for weight management and smoking cessation. Fit & Quit is highly innovative in the areas of the target population, study design, and use of technology. For these reasons, we expect that Fit & Quit will make a significant public health contribution to curtailing the important cessation barrier of post-cessation weight gain.
| Language | English (US) |
|---|---|
| Pages | 31-40 |
| Number of pages | 10 |
| Journal | Contemporary Clinical Trials |
| Volume | 76 |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- Post-cessation weight gain
- Randomized efficacy trial
- Smoking cessation
- Weight gain prevention
- Weight loss
ASJC Scopus subject areas
- Pharmacology (medical)
Cite this
Fit & quit : An efficacy trial of two behavioral post-cessation weight gain interventions. / Salgado García, Francisco I.; Derefinko, Karen J.; Bursac, Zoran; Klesges, Robert C.; Ebbert, Jon Owen; Womack, Catherine R.; Krukowski, Rebecca A.
In: Contemporary Clinical Trials, Vol. 76, 01.01.2019, p. 31-40.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Fit & quit
T2 - Contemporary Clinical Trials
AU - Salgado García, Francisco I.
AU - Derefinko, Karen J.
AU - Bursac, Zoran
AU - Klesges, Robert C.
AU - Ebbert, Jon Owen
AU - Womack, Catherine R.
AU - Krukowski, Rebecca A.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - While smoking cessation leads to significant improvements in both mortality and morbidity, post-cessation weight gain partially attenuates this benefit. Even though post-cessation weight gain is small (4.7 kg on average), it is a stated reason to delay cessation attempts and is associated with smoking relapse. Fit & Quit is a randomized, controlled efficacy trial that aims to examine the ability of a weight stability intervention and a weight loss intervention to reduce post-cessation weight gain. For this purpose, Fit & Quit will randomize participants to three conditions: (a) Small Changes, a weight gain prevention intervention; (b) Look AHEAD Intensive Lifestyle Intervention; and (c) a lower-intensity bibliotherapy intervention. All conditions will receive a highly efficacious behavioral (i.e., rate reduction skills, motivational interviewing) and pharmacological (i.e., varenicline) smoking cessation program. A total of 400 participants will be recruited and randomized to the three interventions. Participants will be recruited in waves, with 10 waves of approximately 40 participants per wave. The primary outcomes of this study include post-cessation weight gain and cessation status at 12-month follow-up. Fit & Quit will integrate and adapt the strongest evidence-based interventions available for weight management and smoking cessation. Fit & Quit is highly innovative in the areas of the target population, study design, and use of technology. For these reasons, we expect that Fit & Quit will make a significant public health contribution to curtailing the important cessation barrier of post-cessation weight gain.
AB - While smoking cessation leads to significant improvements in both mortality and morbidity, post-cessation weight gain partially attenuates this benefit. Even though post-cessation weight gain is small (4.7 kg on average), it is a stated reason to delay cessation attempts and is associated with smoking relapse. Fit & Quit is a randomized, controlled efficacy trial that aims to examine the ability of a weight stability intervention and a weight loss intervention to reduce post-cessation weight gain. For this purpose, Fit & Quit will randomize participants to three conditions: (a) Small Changes, a weight gain prevention intervention; (b) Look AHEAD Intensive Lifestyle Intervention; and (c) a lower-intensity bibliotherapy intervention. All conditions will receive a highly efficacious behavioral (i.e., rate reduction skills, motivational interviewing) and pharmacological (i.e., varenicline) smoking cessation program. A total of 400 participants will be recruited and randomized to the three interventions. Participants will be recruited in waves, with 10 waves of approximately 40 participants per wave. The primary outcomes of this study include post-cessation weight gain and cessation status at 12-month follow-up. Fit & Quit will integrate and adapt the strongest evidence-based interventions available for weight management and smoking cessation. Fit & Quit is highly innovative in the areas of the target population, study design, and use of technology. For these reasons, we expect that Fit & Quit will make a significant public health contribution to curtailing the important cessation barrier of post-cessation weight gain.
KW - Post-cessation weight gain
KW - Randomized efficacy trial
KW - Smoking cessation
KW - Weight gain prevention
KW - Weight loss
UR - http://www.scopus.com/inward/record.url?scp=85056664673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056664673&partnerID=8YFLogxK
U2 - 10.1016/j.cct.2018.11.009
DO - 10.1016/j.cct.2018.11.009
M3 - Article
VL - 76
SP - 31
EP - 40
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
SN - 1551-7144
ER -